无码一区二区三区视频,日本橙人影院一区,日本久久爱一区不卡,小色网淫色网

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73196KIF5B（E15）-RET（E12） V804M/BaF3

KIF5B（E15）-RET（E12） V804M/BaF3
名稱 KIF5B（E15）-RET（E12） V804M/BaF3
型號 CBP73196
報價
特點(diǎn) KIF5B（E15）-RET（E12） [V804M]/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73196
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804M]/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RRPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of  KIF5B-RET [V804M]/BaF3

CBP73196 WB.png


2. Sanger of KIF5B-RET [V804M]/BaF3

CBP73196 sanger1.png

CBP73196 sanger2.png


3. Anti-proliferation assay


CBP73196 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret(S) V804M Cells (C1).




如果你對CBP73196KIF5B（E15）-RET（E12） V804M/BaF3感興趣，想了解更詳細(xì)的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細(xì)地址：

  • 補(bǔ)充說明：

  • 驗(yàn)證碼：

    請輸入計(jì)算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
好吊妞7788| 大香蕉九7成人免费在线观看88c | 日本三级片在线观看 99| 成人亚洲午夜福利| 日韩亚洲欧美乱码| 久久久精品美臀| 悠悠色一区二区| 黄色四季网站| 欧美日韩爆乳中文字幕一区二区三 | 999久久久无 码国产精品| 免费小视频欧美120秒| 99九九黄色片| 久久夫妻生活网站| 亚洲精彩无码久久不卡1区二区| 欧美人妻无码精品一区二区三区| 大香蕉在线大香蕉在| 欧美 国产 一区 3P| 国产成人991| 国产精品,欧美在线| 男人鸡巴无套内射美女网站| 色呦呦日韩一区| 一级黄色电影久久久久| 国产精品一卡av| 免费视频亚洲图片一区 | 大鸡巴操逼逼喷白浆视频| 麻豆中文字幕在线观看| www.老鸭窝在线观看| www.青青草.com| 国产欧美分类电影| 白虎AV一区二区三区| 搞逼不卡视频网| 好吊妇在线看免费网站| 天天色久综合| 亚洲日韩欧美时尚另类综合性爱| 最新欧美日韩在线| 伊人大香蕉在线网站| 亚洲中文字幕久久中文字幕精品| 欧美人妻少妇精品免费久久看| 亚洲精品99久久久| 我要看大毛片| jiujiu麻豆一区二区三区在线 |